Since 2008, 4CYTE™ has undergone rigorous assessment in both laboratory and clinical trials to test its safety and efficacy. Several of these studies have been peer reviewed and published in leading veterinary journals. 4CYTE™ and EPIITALIS^® have demonstrated not only symptom modifying capabilities, but also disease modifying effects. Osteoarthritis is a progressive disease, so treating the underlying ailment rather than treating symptoms alone, is a significant breakthrough in the management of osteoarthritis.